Login to Your Account



Clinic Roundup


Thursday, November 15, 2012
• OncoSec Medical Inc., of San Diego, reported interim results from a Phase IV trial of NeoPulse in skin cancer at the World Meeting of Interdisciplinary Melanoma and Skin Care Centres and EADO Congress in Barcelona, Spain, showing a complete response greater than 90 percent in basal cell carcinoma patients and 70 percent in squamous cell carcinoma patients at six months.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription